Trial Profile

A Phase 2a study of BAER-101

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 7325 (Primary)
Indications Epilepsy; Partial epilepsies; Seizures
Focus Therapeutic Use
Sponsors Avenue Therapeutics

Most Recent Events

09 Aug 2024 According to an Avenue Therapeutics media release, subject to the receipt of additional financing, Avenue continues plans to initiate a Phase 2a clinical trial of BAER-101 in patients with focal epilepsy and other seizure disorders.
04 Aug 2023 New trial record
01 Aug 2023 According to an Avenue Therapeutics media release, company will initiating a Phase 2a study of BAER-101 in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com